Informação da revista
Baixar PDF
Mais opções do artigo
Editorial comment
Open Access
Disponível online em 26 de Maio de 2022
Two years later, azithromycin for COVID-19 and the effect on the heart, is it still relevant?
Dois anos mais tarde, azitromicina para Covid-19 e os seus efeitos cardíacos ainda é relevante?
Sérgio Matoso Laranjoa,b
a Serviço de Cardiologia Pediátrica, Hospital de Santa Marta, Centro Hospitalar e Universitário de Lisboa Central, Portugal
b Comprehensive Health Research Center, Universidade NOVA de Lisboa, Lisboa, Portugal
Informação do artigo
Texto Completo
Baixar PDF
Texto Completo

COVID-19 is an ongoing global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus was first identified from an outbreak in the Chinese city of Wuhan in December 2019.1

For the first two years of the pandemic, no specific effective treatment or cure was available. In the first months of the pandemic, antiviral and immunomodulatory agents were proposed as potential treatments. Drugs such as hydroxychloroquine, lopinavir/ritonavir, ivermectin and azithromycin were reported and tested as potential therapeutic options.2 Azithromycin presented in vitro activity against SARS-CoV-2 and was able to act in different points of the viral cycle, with the main antiviral effect of azithromycin being due to its intracellular alkalizing effect. However, the evidence of its clinical use was always scarce and of low quality. A recent systematic review of the available clinical trials revealed that the routine use of azithromycin as therapy in Covid-19 patients was not justified, due to its lack of efficacy and potential risk of bacterial resistance that was not offset by an increased clinical benefit.3,4

The proarrhythmic effects of azithromycin are well known,5 resulting in prolonged ventricular repolarization, which associated with the tropism of SARS-CoV-2 for cardiomyocytes, has raised well-founded concerns regarding the use of this drug, particularly in association with hydroxychloroquine, as it could potentially lead to a severely prolonged QTc interval.6 Several of the therapeutic protocols even proposed the serial electrocardiographic monitoring of these patients. Several studies have since demonstrated the safety of the drug, within therapeutic doses, despite its ineffectiveness for its primary objective.

Regardless of these premises, and reporting from the last two years, the mass use of azithromycin has served as a laboratory experiment to assess the impact of the drug on certain electrocardiographic properties. In the current issue of this journal, Sunkak and et al.7 seek to detail the effects of azithromycin on ventricular repolarization in children with COVID-19. The study included 105 pediatric patients who were hospitalized between June and August 2020 in a single center Pediatric Infection Diseases Clinic, with a positive COVID-19 PCR test and treated with oral azithromycin. In this study, oral azithromycin had no effect on QTc, Tp-ec, QTc, or Tp-ec dispersion or the Tp-ec/QTc ratio in children with COVİD-19. Hence, in the authors experience, oral azithromycin treatment alone did not affect ventricular repolarization in children with COVID-19 and appeared to be safe in asymptomatic or mildly symptomatic patients.

Nevertheless, as we have previously stated, for hydroxychloroquine to be used in pediatric patients in the same setting,8 the direct cardiac toxicity of SARS-CoV-2 and the relative contribution of concomitant drugs to the reported cardiac adverse effects in COVID-19 patients needs to be further studied and be better evaluated.

Conflicts of interest

The author has no conflicts of interest to declare.

WHO Statement on the Second Meeting of the International Health Regulations (2005). Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV).
R.A. Siemieniuk, J.J. Bartoszko, L. Ge, et al.
Drug treatments for COVID-19: living systematic review and network meta-analysis.
BMJ (Clin Res Ed), 370 (2020), pp. m2980
A.M. Kamel, M. Monem, N.A. Sharaf, et al.
Efficacy and safety of azithromycin in COVID-19 patients: a systematic review and meta-analysis of randomized clinical trials.
Rev Med Virol, 32 (2022), pp. e2258
C. Johnston, E.R. Brown, J. Stewart, et al.
COVID-19 Early Treatment Study Team. Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: a randomized clinical trial.
EClinicalMedicine, 33 (2021), pp. 100773
J.R. Giudicessi, M.J. Ackerman.
Azithromycin and risk of sudden cardiac death: guilty as charged or falsely accused?.
Cleveland Clin J Med, 80 (2013), pp. 539-544
N.J. Mercuro, C.F. Yen, D.J. Shim, et al.
Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for Coronavirus disease 2019 (COVID-19).
JAMA Cardiol, 5 (2020), pp. 1036-1041
S. Suleyman, M. Argun, B. Celik, et al.
Effects of azithromycin on ventricular repolarization in children with COVID-19.
Rev Port Cardiol, 41 (2022),
I. Hormigo, T.M. Silva, S. Laranjo, et al.
Protocol-based cardiotoxicity monitoring in hydroxychloroquine medicated COVID-19 pediatric patients.
Copyright © 2022. Sociedade Portuguesa de Cardiologia
Revista Portuguesa de Cardiologia

Receba a nossa Newsletter

Opções de artigo
en pt

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Ao assinalar que é «Profissional de Saúde», declara conhecer e aceitar que a responsável pelo tratamento dos dados pessoais dos utilizadores da página de internet da Revista Portuguesa de Cardiologia (RPC), é esta entidade, com sede no Campo Grande, n.º 28, 13.º, 1700-093 Lisboa, com os telefones 217 970 685 e 217 817 630, fax 217 931 095 e com o endereço de correio eletrónico Declaro para todos os fins, que assumo inteira responsabilidade pela veracidade e exatidão da afirmação aqui fornecida.